Status:
COMPLETED
Monocyte Function and Inflammation in Type 1 Diabetes and Its Modulation
Lead Sponsor:
University of California, Davis
Collaborating Sponsors:
Juvenile Diabetes Research Foundation
National Institutes of Health (NIH)
Conditions:
Type 1 Diabetes
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
Type I diabetes (T1DM) is associated with an increased risk of vascular complications. While the precise mechanism(s) by which diabetes accelerates atherosclerosis has not been elucidated, several lin...
Detailed Description
Type I diabetes (T1DM) is associated with an increased risk of vascular complications. While the precise mechanism(s) by which diabetes accelerates atherosclerosis has not been elucidated, several lin...
Eligibility Criteria
Inclusion
- Type I diabetic patients (onset \< 20years and on insulin therapy since diagnosis) without clinical macrovascular complications, present age \> 20 years with duration of diabetes \> 1yr.
Exclusion
- HbA1c over the last year \>10%
- Patients on glucophage and/or the thiazolidenediones will be excluded, since these drugs appear to be anti-inflammatory.
- Theumatoid arthritis;
- Abnormal liver function,
- Hypo- or hyperthyroidism;
- Malabsorption;
- Steroid therapy,
- Anti-inflammatory drugs except aspirin (81mg/day)
- Pregnancy,
- Lactation,
- Smoking,
- Abnormal complete blood count; and
- Alcohol consumption \> 1 oz/day
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
End Date :
July 1 2005
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00441844
Start Date
October 1 2002
End Date
July 1 2005
Last Update
March 1 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCDavis Medical Center
Sacramento, California, United States, 95817